<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.2217/nnm-2017-0198</dc:identifier><dc:language>eng</dc:language><dc:creator>Schwinté, P.</dc:creator><dc:creator>Mariotte, A.</dc:creator><dc:creator>Anand, P.</dc:creator><dc:creator>Keller, L.</dc:creator><dc:creator>Idoux-Gillet, Y.</dc:creator><dc:creator>Huck, O.</dc:creator><dc:creator>Fioretti, F.</dc:creator><dc:creator>Tenenbaum, H.</dc:creator><dc:creator>Georgel, P.</dc:creator><dc:creator>Wenzel, W.</dc:creator><dc:creator>Irusta, S.</dc:creator><dc:creator>Benkirane-Jessel, N.</dc:creator><dc:title>Anti-inflammatory effect of active nanofibrous polymeric membrane bearing nanocontainers of atorvastatin complexes</dc:title><dc:identifier>ART-2017-103538</dc:identifier><dc:description>Aim: We developed polymeric membranes for local administration of nonsoluble anti-inflammatory statin, as potential wound patch in rheumatic joint or periodontal lesions. Methods: Electrospun polycaprolactone membranes were fitted with polysaccharide-atorvastatin nanoreservoirs by using complexes with poly-aminocyclodextrin. Characterization methods are UV-Visible and X-ray photoelectron spectroscopy, molecular dynamics, scanning and transmission electron microscopy. In vitro, membranes were seeded with macrophages, and inflammatory cytokine expression were monitored. Results &amp;amp; conclusion: Stable inclusion complexes were formed in solution (1:1 stability constant 368 M- 1, -117.40 kJ mol- 1), with supramolecular globular organization (100 nm, substructure 30 nm). Nanoreservoir technology leads to homogeneous distribution of atorvastatin calcium trihydrate complexes in the membrane. Quantity embedded was estimated (70-90 µg in 30 µm × 6 mm membrane). Anti-inflammatory effect by cell contact-dependent release reached 60% inhibition for TNF-a and 80% for IL-6. The novelty resides in the double protection offered by the cyclodextrins as drug molecular chaperones, with further embedding into biodegradable nanoreservoirs. The strategy is versatile and can target other diseases.</dc:description><dc:date>2017</dc:date><dc:source>http://zaguan.unizar.es/record/75705</dc:source><dc:doi>10.2217/nnm-2017-0198</dc:doi><dc:identifier>http://zaguan.unizar.es/record/75705</dc:identifier><dc:identifier>oai:zaguan.unizar.es:75705</dc:identifier><dc:identifier.citation>Nanomedicine 12, 23 (2017), 2651-2674</dc:identifier.citation><dc:rights>All rights reserved</dc:rights><dc:rights>http://www.europeana.eu/rights/rr-f/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>